Wuhan General Group (China), Inc.
Built from real-time financials, refreshed daily. For a full Analyst Grade with bull/bear case, price targets, and qualitative risk analysis, generate a WUHN research report →
About the company
Wuhan General Group (China), Inc. is a nutraceutical biotechnology company, which engages in the development of alternative plant-based cannabinoids and psilocybin medical research that commercializes a range of cannabidiol and mushrooms-based products under the Dr. AnnaRx, Medspresso and Handcrafted Delights brands.
- CEO
- Jeff Robinson
- IPO
- 2006
- Employees
- 700
- HQ
- Cape Town, NV, US
Price Chart
- Market Cap
- $16.55K
- P/E
- -0.01
- P/S
- 1.17
- P/B
- 0.03
- EV/EBITDA
- 0.00
- Div Yield
- 0.00%
- Gross Margin
- 9.70%
- Op Margin
- -11882.90%
- Net Margin
- -12086.93%
- ROE
- -316.07%
- ROIC
- -254.74%
- Revenue
- $14.18K · -57.40%
- Net Income
- $-1,713,443 · -517.92%
- EPS
- $-0.03 · -494.94%
- Op Income
- $-1,684,520
- FCF YoY
- -3251.25%
- 52W High
- $0.00
- 52W Low
- $0.00
- 50D MA
- $0.00
- 200D MA
- $0.00
- Beta
- -3.45
- Avg Volume
- 1.48K
Get TickerSpark's AI analysis on WUHN
Create an account to generate AI analysis on any ticker — technical setup, analyst consensus, earnings watch, insider pulse, financial health, and peer context. Ready in about a minute.
Get Pro Access →Already have an account? Log in
Our WUHN coverage
Recent articles, reports, and earnings notes.
No research on WUHN yet
For a full analyst-grade research report — grades, price targets, financials, chart analysis — generate one on demand.
Generate WUHN report →Similar companies
Peers in the same neighborhood.